{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:23:01Z","timestamp":1784859781842,"version":"3.55.0"},"reference-count":72,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current guideline recommendations for primary prophylaxis of venous thromboembolism (VTE) are based on randomized clinical trials that usually exclude subjects at a potentially high risk of bleeding complications. For this reason, no specific guideline is available for thromboprophylaxis in hospitalized patients with thrombocytopenia and\/or platelet dysfunction. However, except in patients with absolute contraindications to anticoagulant drugs, antithrombotic prophylaxis should always be considered, for example, in hospitalized cancer patients with thrombocytopenia, especially in those with multiple VTE risk factors. Low platelet number, platelet dysfunction, and clotting abnormalities are also very common in patients with liver cirrhosis, but these patients have a high incidence of portal venous thrombosis, implying that cirrhotic coagulopathy does not fully protect against thrombosis. These patients may benefit from antithrombotic prophylaxis during hospitalization. Patients hospitalized for COVID-19 need prophylaxis, but frequently experience thrombocytopenia or coagulopathy. In patients with antiphospholipid antibodies, a high thrombotic risk is usually present, even in the presence of thrombocytopenia. VTE prophylaxis in high-risk conditions is thus suggested in these patients. At variance with severe thrombocytopenia (&lt; 50,000\/mm3), mild\/moderate thrombocytopenia (\u2265 50,000\/mm3) should not interfere with VTE prevention decisions. In patients with severe thrombocytopenia, pharmacological prophylaxis should be considered on an individual basis. Aspirin is not as effective as heparins in lowering the risk of VTE. Studies in patients with ischemic stroke demonstrated that thromboprophylaxis with heparins is safe in these patients also during antiplatelet treatment. The use of direct oral anticoagulants in the prophylaxis of VTE in internal medicine patients has been recently evaluated, but no specific recommendation exists for patients with thrombocytopenia. The need for VTE prophylaxis in patients on chronic treatment with antiplatelet agents should be evaluated after assessing the individual risk of bleeding complications. Finally, the selection of patients who require post-discharge pharmacological prophylaxis remains debated. New molecules currently under development (such as the inhibitors of factor XI) may contribute to improve the risk\/benefit ratio of VTE primary prevention in this setting of patients.<\/jats:p>","DOI":"10.1055\/s-0043-1769013","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:37:06Z","timestamp":1684449426000},"page":"096-103","source":"Crossref","is-referenced-by-count":5,"title":["Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years"],"prefix":"10.1055","volume":"50","author":[{"given":"Antonella","family":"Tufano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, \u201cFederico II\u201d University of Naples, Via Sergio Pansini, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","article-title":"A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study","volume":"151","author":"F A Anderson Jr","year":"1991","journal-title":"Arch Intern Med"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.1988.00380060189033","article-title":"Fatal pulmonary emboli in hospitalized patients. An autopsy study","volume":"148","author":"I Rubinstein","year":"1988","journal-title":"Arch Intern Med"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1538-7836.2005.01458.x","article-title":"The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism","volume":"3","author":"G Di Minno","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of VTE in acutely ill medical patients. Prophylaxis in Medical Patients Study Group","volume":"341","author":"M M Samama","year":"1999","journal-title":"N Engl J Med"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"A Leizorovicz","year":"2004","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"A T Cohen","year":"2006","journal-title":"BMJ"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: ACCP evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"W H Geerts","year":"2008","journal-title":"Chest"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1378\/chest.06-2993","article-title":"Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism","volume":"132","author":"V F Tapson","year":"2007","journal-title":"Chest"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1538-7836.2004.01012.x","article-title":"The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients: findings from the RIETE Registry","volume":"2","author":"M Monreal","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(08)60202-0","article-title":"Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study","volume":"371","author":"A T Cohen","year":"2008","journal-title":"Lancet"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/jth.15607","article-title":"An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day Steering Committee: systematic review and meta-analysis","volume":"20","author":"G Forgo","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0031-1273088","article-title":"Prevention of venous thromboembolism: focus on mechanical prophylaxis","volume":"37","author":"G Lippi","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"14","key":"ref13","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/14656566.2022.2128757","article-title":"Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients","volume":"23","author":"D Santagata","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"S Barbar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2008.07089.x","article-title":"Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients","volume":"141","author":"P Prandoni","year":"2008","journal-title":"Br J Haematol"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jhm.562","article-title":"Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model","volume":"5","author":"G A Maynard","year":"2010","journal-title":"J Hosp Med"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11739-018-1829-7","article-title":"Prophylaxis of venous thromboembolism in internal medicine units: the RAMs issue","volume":"13","author":"A Tufano","year":"2018","journal-title":"Intern Emerg Med"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0031-1273090","article-title":"Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature","volume":"37","author":"A Tufano","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11739-018-1956-1","article-title":"Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer","volume":"14","author":"D Prisco","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 International Clinical Practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 International Clinical Practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref22","first-page":"S0923","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial","volume":"4","author":"J I Zwicker","year":"2020","journal-title":"Blood Adv"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ajh.24700","article-title":"Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool","volume":"92","author":"R Patell","year":"2017","journal-title":"Am J Hematol"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial","volume":"153","author":"R D Hull","year":"2010","journal-title":"Ann Intern Med"},{"issue":"23","key":"ref26","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"S Z Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"A T Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/jth.12683","article-title":"Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH","volume":"12","author":"M Di Nisio","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/jth.15829","article-title":"Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: guidance from the SSC of the ISTH","volume":"20","author":"L N Roberts","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"N Afdhal","year":"2008","journal-title":"J Hepatol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.15239","article-title":"The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC working group on hemostatic management of patients with liver disease","volume":"19","author":"T Lisman","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11739-009-0345-1","article-title":"New concepts of coagulation and bleeding in liver disease","volume":"5","author":"P G Northup","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11739-009-0302-z","article-title":"Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged","volume":"5","author":"A Tripodi","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","article-title":"Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism","volume":"101","author":"P G Northup","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/17474086.2022.2144217","article-title":"Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges","volume":"15","author":"V La Mura","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ajg.2016.498","article-title":"Changing concepts of cirrhotic coagulopathy","volume":"112","author":"A Tripodi","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1160\/TH16-06-0450","article-title":"The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis","volume":"117","author":"P Ambrosino","year":"2017","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.15562","article-title":"Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH","volume":"20","author":"L N Roberts","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1111\/liv.15001","article-title":"Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure","volume":"41","author":"E Campello","year":"2021","journal-title":"Liver Int"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"N Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"C Wu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s11739-020-02432-x","article-title":"COVID-19, coagulopathy and venous thromboembolism: more questions than answers","volume":"15","author":"M Marietta","year":"2020","journal-title":"Intern Emerg Med"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00277-020-04366-y","article-title":"Hematologic disorders associated with COVID-19: a review","volume":"100","author":"M S Rahi","year":"2021","journal-title":"Ann Hematol"},{"issue":"20","key":"ref44","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.3390\/jcm11205997","article-title":"Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: a consensus statement based on available clinical trials","volume":"11","author":"K G Kyriakoulis","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"S Schulman","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref46","first-page":"48","article-title":"A re-appraisal of thrombogenesis in COVID-19, seen as a multiple complex system. Bleeding","volume":"1","author":"S Coccheri","year":"2022","journal-title":"Thrombosis and Vascular Biology"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.2021012247","article-title":"Clinical features of thrombosis and bleeding in COVID-19","volume":"140","author":"M R Thomas","year":"2022","journal-title":"Blood"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tcm.2022.02.008","article-title":"Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination","volume":"32","author":"T Iba","year":"2022","journal-title":"Trends Cardiovasc Med"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/jth.14848","article-title":"Thrombocytopenia and its association with mortality in patients with COVID-19","volume":"18","author":"X Yang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/hematology.2022000403","article-title":"To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients","volume":"2022","author":"A C Spyropoulos","year":"2022","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/rth2.12486","article-title":"Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19","volume":"5","author":"A C Spyropoulos","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s11239-021-02504-5","article-title":"External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19","volume":"52","author":"M Goldin","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"E Ramacciotti","year":"2022","journal-title":"Lancet"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"2013","author":"W Lim","year":"2013","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"S Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"101015","DOI":"10.1016\/j.blre.2022.101015","article-title":"Hematological manifestations of antiphospholipid syndrome: going beyond thrombosis","volume":"58","author":"G El Hasbani","year":"2023","journal-title":"Blood Rev"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.thromres.2014.11.027","article-title":"Endothelial and platelet microparticles in patients with antiphospholipid antibodies","volume":"135","author":"K A Breen","year":"2015","journal-title":"Thromb Res"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"V Proulle","year":"2014","journal-title":"Blood"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000327506","article-title":"Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity","volume":"37","author":"M A Cikrikcioglu","year":"2010","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"09","key":"ref60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00043426-200309000-00017","article-title":"Evans syndrome associated with antiphospholipid antibodies","volume":"25","author":"T Avcin","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"ref61","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"M G Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref62","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force Report on antiphospholipid syndrome treatment trends","volume":"29","author":"H Cohen","year":"2020","journal-title":"Lupus"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11926-021-01051-5","article-title":"An update on antiphospholipid syndrome","volume":"23","author":"E Xourgia","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"06","key":"ref64","first-page":"544","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"74","author":"J P Collet","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"07","key":"ref65","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jhm.2047","article-title":"A systematic review of venous thromboembolism prophylaxis strategies in patients with renal insufficiency, obesity, or on antiplatelet agents","volume":"8","author":"S Kebede","year":"2013","journal-title":"J Hosp Med"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1076029611412362","article-title":"Prevention of deep vein thrombosis and pulmonary embolism in patients with stroke","volume":"18","author":"T S Field","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archneur.1992.00530270093024","article-title":"Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability","volume":"49","author":"G Landi","year":"1992","journal-title":"Arch Neurol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(07)60633-3","article-title":"The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison","volume":"369","author":"D G Sherman","year":"2007","journal-title":"Lancet"},{"issue":"04","key":"ref69","first-page":"CD000024","article-title":"Anticoagulants for acute ischaemic stroke","volume":"4","author":"P AG Sandercock","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"04","key":"ref70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"R De Caterina","year":"2023","journal-title":"Eur Heart J"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/VHRM.S331614","article-title":"Factor XI inhibition for the prevention of venous thromboembolism: an update on current evidence and future perspectives","volume":"18","author":"G Poenou","year":"2022","journal-title":"Vasc Health Risk Manag"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"903029","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"S Nopp","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1769013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:54:05Z","timestamp":1730804045000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1769013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":72,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,2]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1769013","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}